المؤلفون: Ahluwalia, Tarunveer S., Rönkkö, Teemu K.E., Eickhoff, Mie K., Curovic, Viktor Rotbain, Siwy, Justyna, Eder, Susanne, Denicolò, Sara, Mayer, Gert, Mischak, Harald, Rossing, Peter, Persson, Frederik

المصدر: Ahluwalia , T S , Rönkkö , T K E , Eickhoff , M K , Curovic , V R , Siwy , J , Eder , S , Denicolò , S , Mayer , G , Mischak , H , Rossing , P & Persson , F 2024 , ' Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease ' , Kidney International Reports , vol. 9 , no. 2 , pp. 334-346 . https://doi.org/10.1016/j.ekir.2023.11.020Test

مصطلحات موضوعية: dapagliflozin, diabetic kidney disease, randomized controlled trial, SGLT2, sodium-glucose cotransporter 2 inhibitors, urinary proteomics

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1016/j.ekir.2023.11.020Test
https://curis.ku.dk/portal/da/publications/randomized-trial-of-sglt2-inhibitor-identifies-target-proteins-in-diabetic-kidney-diseaseTest(2934e856-000c-487c-8f33-6871fd467a4d).html
https://curis.ku.dk/ws/files/381719085/1_s2.0_S246802492301608X_main_1_.pdfTest

المؤلفون: Yi, Tae Won, Smyth, Brendan, Di Tanna, Gian Luca, Arnott, Clare, Cardoza, Kathryn, Kang, Amy, Pollock, Carol, Agarwal, Rajiv, Bakris, George, Charytan, David M., de Zeeuw, Dick, Heerspink, Hiddo J.L., Neal, Bruce, Wheeler, David C., Cannon, Christopher P., Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Levin, Adeera, Mahaffey, Kenneth W., Jardine, Meg J.

المصدر: CREDENCE Trial Investigators , Yi , T W , Smyth , B , Di Tanna , G L , Arnott , C , Cardoza , K , Kang , A , Pollock , C , Agarwal , R , Bakris , G , Charytan , D M , de Zeeuw , D , Heerspink , H J L , Neal , B , Wheeler , D C , Cannon , C P , Zhang , H , Zinman , B , Perkovic , V , Levin , A , Mahaffey , K W & Jardine , M J 2023 ....

مصطلحات موضوعية: age, canagliflozin, cardiovascular outcomes, chronic kidney disease, diabetes, Diabetic kidney disease, kidney outcomes, sex, sodium/glucose cotransporter 2 inhibitors

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/3c7942ae-2565-40e5-83bd-03275fb620a8Test

الإتاحة: https://doi.org/10.1053/j.ajkd.2022.12.015Test
https://hdl.handle.net/11370/3c7942ae-2565-40e5-83bd-03275fb620a8Test
https://research.rug.nl/en/publications/3c7942ae-2565-40e5-83bd-03275fb620a8Test
https://pure.rug.nl/ws/files/702757396/1-s2.0-S0272638623005371-main.pdfTest

المؤلفون: Riley, David R., Essa, Hani, Austin, Philip, Preston, Frank, Kargbo, Isatu, Ibarburu, Gema Hernández, Ghuman, Ramandeep, Cuthbertson, Daniel J., Lip, Gregory Y. H., Alam, Uazman

المصدر: Riley , D R , Essa , H , Austin , P , Preston , F , Kargbo , I , Ibarburu , G H , Ghuman , R , Cuthbertson , D J , Lip , G Y H & Alam , U 2023 , ' All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes ' , Diabetes, Obesity and Metabolism , vol. 25 , no. 10 , pp. 2897-2909 . https://doi.org/10.1111/dom.15185Test

مصطلحات موضوعية: cardiovascular disease, chronic kidney disease, glucagon-like peptide-1 receptor agonists, hospitalization, mortality, sodium-glucose cotransporter 2 inhibitors, type 2 diabetes

وصف الملف: application/pdf

العلاقة: https://vbn.aau.dk/da/publications/cf820eea-d639-415b-842e-65309c57deb6Test

الإتاحة: https://doi.org/10.1111/dom.15185Test
https://vbn.aau.dk/da/publications/cf820eea-d639-415b-842e-65309c57deb6Test
https://vbn.aau.dk/ws/files/551304018/Diabetes_Obesity_Metabolism_-_2023_-_Riley_-_All_cause_mortality_and_cardiovascular_outcomes_with_sodium_glucose.pdfTest
http://www.scopus.com/inward/record.url?scp=85164188429&partnerID=8YFLogxKTest

المؤلفون: Nabrdalik-Leśniak, Diana, Nabrdalik, Katarzyna, Irlik, Krzysztof, Janota, Oliwia, Kwiendacz, Hanna, Szromek-Białek, Paulina, Maziarz, Mirosław, Stompór, Tomasz, Gumprecht, Janusz, Lip, Gregory Y. H.

المصدر: Nabrdalik-Leśniak , D , Nabrdalik , K , Irlik , K , Janota , O , Kwiendacz , H , Szromek-Białek , P , Maziarz , M , Stompór , T , Gumprecht , J & Lip , G Y H 2023 , ' The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes ' , Endokrynologia Polska , vol. 74 , no. 4 , pp. 349-362 . https://doi.org/10.5603/EP.a2023.0039Test

مصطلحات موضوعية: chronic kidney disease, diabetes mellitus, heart failure, oxidative stress, sodium-glucose cotransporter 2 inhibitors

وصف الملف: application/pdf

العلاقة: https://vbn.aau.dk/da/publications/4cf4ed67-8bef-4919-8a70-d9f2f527df12Test

الإتاحة: https://doi.org/10.5603/EP.a2023.0039Test
https://vbn.aau.dk/da/publications/4cf4ed67-8bef-4919-8a70-d9f2f527df12Test
https://vbn.aau.dk/ws/files/609818009/94348-395515-1-PB.pdfTest
http://www.scopus.com/inward/record.url?scp=85176548893&partnerID=8YFLogxKTest

المؤلفون: Wu, Jiajia, Cai, Hong, Xia, Jia, Zhang, Tianyi, Yan, Jiayi, Shao, Xinhua, Wang, Amanda Ying, Shen, Jianxiao, Mou, Shan

المصدر: Wu , J , Cai , H , Xia , J , Zhang , T , Yan , J , Shao , X , Wang , A Y , Shen , J & Mou , S 2023 , ' SGLT2i : therapeutic options or contributing factors of contrast-induced acute kidney injury in the setting of non-diabetes? ' , Pharmacological Research , vol. 195 , 106883 , pp. 1-4 . https://doi.org/10.1016/j.phrs.2023.106883Test

مصطلحات موضوعية: Contrast induced acute kidney injury (CI-AKI), Non-diabetes, Predisposing factors, Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Treatment measures

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1016/j.phrs.2023.106883Test
https://researchers.mq.edu.au/en/publications/5beca792-01da-4513-b27a-076c7572e6baTest
https://research-management.mq.edu.au/ws/files/343730956/Publisher_version_open_access_.pdfTest
http://www.scopus.com/inward/record.url?scp=85166678206&partnerID=8YFLogxKTest

المؤلفون: Wu, Mei Zhen, Chandramouli, Chanchal, Wong, Pui Fai, Chan, Yap Hang, Li, Hang Long, Yu, Si Yeung, Tse, Yi Kei, Ren, Qing Wen, Yu, Shuk Yin, Tse, Hung Fat, Lam, Carolyn S.P., Yiu, Kai Hang

المصدر: Wu , M Z , Chandramouli , C , Wong , P F , Chan , Y H , Li , H L , Yu , S Y , Tse , Y K , Ren , Q W , Yu , S Y , Tse , H F , Lam , C S P & Yiu , K H 2022 , ' Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors ' , Diabetes and Metabolism , vol. 48 , no. 6 , 101367 . https://doi.org/10.1016/j.diabet.2022.101367Test

مصطلحات موضوعية: Dipeptidyl peptidase 4 inhibitors, Infection-related death, Pneumonia, Pneumonia-related death, Sepsis, Sepsis-related death, Sodium-glucose cotransporter 2 inhibitors

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/d87765a7-cfd9-43fb-8085-f12f1eb0ad45Test

الإتاحة: https://doi.org/10.1016/j.diabet.2022.101367Test
https://hdl.handle.net/11370/d87765a7-cfd9-43fb-8085-f12f1eb0ad45Test
https://research.rug.nl/en/publications/d87765a7-cfd9-43fb-8085-f12f1eb0ad45Test
https://pure.rug.nl/ws/files/250896142/1_s2.0_S1262363622000490_main.pdfTest

المؤلفون: Norre, Tobias, Grimm, Daniela, Simonsen, Ulf

المصدر: Norre , T , Grimm , D & Simonsen , U 2022 , ' Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and vericiguat for congestive heart failure therapy ' , Basic & Clinical Pharmacology & Toxicology , vol. 130 , no. 4 , pp. 425-438 . https://doi.org/10.1111/bcpt.13714Test

مصطلحات موضوعية: clinical trials, heart failure, sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, vericiguat, GUANYLATE-CYCLASE STIMULATOR, NEPRILYSIN INHIBITION, CARDIOVASCULAR OUTCOMES, NATRIURETIC PEPTIDE, BLOOD-PRESSURE, REDUCED EJECTION FRACTION, DOUBLE-BLIND, NITRIC-OXIDE, valsartan, LCZ696, sacubitril, QUALITY-OF-LIFE, Valsartan/adverse effects, Humans, Tetrazoles/adverse effects, Pyrimidines, Angiotensin Receptor Antagonists/therapeutic use, Glucose/therapeutic use, Aminobutyrates/adverse effects, Treatment Outcome, Biphenyl Compounds, Heart Failure/drug therapy, Sodium, Heterocyclic Compounds, 2-Ring

العلاقة: https://pure.au.dk/portal/en/publications/cacca6d6-d2ec-4c55-afce-79ce59ed97caTest

الإتاحة: https://doi.org/10.1111/bcpt.13714Test
https://pure.au.dk/portal/en/publications/cacca6d6-d2ec-4c55-afce-79ce59ed97caTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306855/pdf/BCPT-130-425.pdfTest

المؤلفون: Butt, Jawad H., Adamson, Carly, Docherty, Kieran F., de Boer, Rudolf A., Petrie, Mark C., Inzucchi, Silvio E., Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Bengtsson, Olof, Schou, Morten, O'Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Jhund, Pardeep S., McMurray, John J.V., Køber, Lars

المصدر: Butt , J H , Adamson , C , Docherty , K F , de Boer , R A , Petrie , M C , Inzucchi , S E , Kosiborod , M N , Langkilde , A M , Lindholm , D , Martinez , F A , Bengtsson , O , Schou , M , O'Meara , E , Ponikowski , P , Sabatine , M S , Sjöstrand , M , Solomon , S D , Jhund , P S , McMurray , J J V & Køber , L 2021 , ' Efficacy and Safety ....

مصطلحات موضوعية: Clinical trials, Heart failure with reduced ejection fraction, Natriuretic peptides, Sodium-glucose cotransporter 2 inhibitors

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/f986c110-f3b5-45eb-a2b3-c3d64950c073Test

الإتاحة: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008837Test
https://hdl.handle.net/11370/f986c110-f3b5-45eb-a2b3-c3d64950c073Test
https://research.rug.nl/en/publications/f986c110-f3b5-45eb-a2b3-c3d64950c073Test
https://pure.rug.nl/ws/files/199939359/Efficacy_and_Safety_of_Dapagliflozin_in_Heart_Failure_With_Reduced_Ejection_Fraction_According_to_N_Terminal_Pro_B_Type_Natriuretic_Peptide_Insights_From_the_DAPA_HF_Trial.pdfTest

المؤلفون: Kristensen, Kasper B., Henriksen, Daniel P., Hallas, Jesper, Pottegård, Anton, Lund, Lars C.

المصدر: Kristensen , K B , Henriksen , D P , Hallas , J , Pottegård , A & Lund , L C 2021 , ' Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis ' , Diabetologia , vol. 64 , no. 7 , pp. 1563-1571 . https://doi.org/10.1007/s00125-021-05424-4Test

مصطلحات موضوعية: Cohort studies, Databases, Dipeptidyl peptidase 4 inhibitors, Glucagon–like peptide 1 receptor agonists, Nephrolithiasis, Observational studies, Sodium–glucose cotransporter 2 inhibitors, Type 2 diabetes

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/551ebf05-6eaf-4e91-a677-0211a789f3d7Test

الإتاحة: https://doi.org/10.1007/s00125-021-05424-4Test
https://portal.findresearcher.sdu.dk/da/publications/551ebf05-6eaf-4e91-a677-0211a789f3d7Test
https://findresearcher.sdu.dk/ws/files/182136575/Kristensen_sdulib.pdfTest

المؤلفون: Zhang, Jingyi, Van Spall, Harriette GC., Li, Likang, Khan, Mohammad Shahzeb, Pandey, Ambarish, Thabane, Lehana, Bai, Xuerui, Wang, Yaoyao, Lip, Gregory YH., Li, Guowei

المصدر: Zhang , J , Van Spall , H GC , Li , L , Khan , M S , Pandey , A , Thabane , L , Bai , X , Wang , Y , Lip , G YH & Li , G 2023 , ' Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus ' , Diabetes & Metabolic Syndrome: Clinical Research & Reviews , vol. 17 , no. 7 , 102804 . https://doi.org/10.1016/j.dsx.2023.102804Test

مصطلحات موضوعية: Cardiovascular outcomes, Glucagon-like peptide-1 receptor agonists, Kidney outcomes, Race, Sodium-glucose cotransporter 2 inhibitors, Type 2 diabetes mellitus

العلاقة: https://vbn.aau.dk/da/publications/27320673-443f-43f1-95c2-b7cd1ef39c21Test

الإتاحة: https://doi.org/10.1016/j.dsx.2023.102804Test
https://vbn.aau.dk/da/publications/27320673-443f-43f1-95c2-b7cd1ef39c21Test